NL
DE
Biochemical recurrence occurs in >20% of treated prostate cancer patients, mainly due to metastatic disease (>80%). In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT. Biomaterial from eligible ADOPT patients will be used to establish the ADOPT biobank. Patients eligible for the ADOPT study will be asked to consent to blood collection prior to treatment and during 6 and 12 month follow-up. The ADOPT biobank plans to use new technology to identify and validate circulating tumor DNA (ctDNA) and extracellular vesicle (EV) biomarker. These will then be used as predictive and prognostic tools to improve the timing of clinical treatment and to more accurately monitor treatment response.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Process and time constraints for external sample issuance
6 May 2025Prior to issuing samples intended for an external applicant, the Radboud Biobank first draws up a quotation of the expected costs. This process will lead to some delays in distribution.
read more
Periodic invoicing biobank collections
6 May 2025As of this year, the Radboud Biobank will periodically charge biobank collections for the processing and storage costs incurred.
read more
National Biobanks & Collections Dag 2025
6 May 2025The second edition of the National Biobanks & Collections Day took place on March 27, 2025, in Nijmegen and attracted 150 participants from all over the Netherlands.
read moreRadboud Biobank Office Relocation
30 January 2025We would like to inform you about the upcoming relocation of the Radboud Biobank office.
read more
Request for DNA samples from stored whole blood and/or saliva
30 January 2025There are biobank collections that collected whole blood and saliva before joining the Radboud Biobank to isolate DNA from them later.
read more
Great news!
30 January 2025We have good news for both new and existing collections and projects interested in isolating PBMCs (Peripheral Blood Mononuclear Cells)!
read more